0.242
19.33%
-0.058
Ampio Pharmaceuticals Inc stock is currently priced at $0.242, with a 24-hour trading volume of 15,034.
It has seen a -19.33% decreased in the last 24 hours and a -85.60% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.275 pivot point. If it approaches the $0.16 support level, significant changes may occur.
Ampio Pharmaceuticals Inc Stock (AMPE) Financials Data
Ampio Pharmaceuticals Inc (AMPE) Net Income 2024
AMPE net income (TTM) was -$8.80 million for the quarter ending September 30, 2023, a +56.75% increase year-over-year.
Ampio Pharmaceuticals Inc (AMPE) Cash Flow 2024
AMPE recorded a free cash flow (TTM) of -$10.55 million for the quarter ending September 30, 2023, a +48.64% increase year-over-year.
Ampio Pharmaceuticals Inc (AMPE) Earnings per Share 2024
AMPE earnings per share (TTM) was -$12.05 for the quarter ending September 30, 2023, a +68.99% growth year-over-year.
Ampio Pharmaceuticals Inc Stock (AMPE) Latest News
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Why LumiraDx Shares Are Trading Lower By Over 30%; Here Are 20 Stocks Moving Premarket
Benzinga
Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Why Bridgeline Digital Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Titan Machinery Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Why Salesforce Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Benzinga
About Ampio Pharmaceuticals Inc
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee; and Optina, an oral agent for the treatment of diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.
Cap:
|
Volume (24h):